Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response rate and response duration with the
combination of low-dose rituximab, eltrombopag and high-dose dexamethasone.